Xspray Pharma AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2003-01-10
- Employees
- 26
- Market Cap
- -
- Website
- https://xspraypharma.com
Clinical Trials
6
Active:0
Completed:6
Trial Phases
2 Phases
Phase 1:4
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (66.7%)Not Applicable
2 (33.3%)Bioavailability Study of XS003 (Nilotinib)
Not Applicable
Completed
- Conditions
- Cancer
- Interventions
- Drug: XS003 under fed and fasted condition
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Xspray Pharma AB
- Target Recruit Count
- 48
- Registration Number
- NCT07138352
- Locations
- 🇺🇸
QPS Missouri, Springfield, Missouri, United States
A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.
Not Applicable
Completed
- Conditions
- Cancer
- Interventions
- Drug: XS003 (nilotinib)
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Xspray Pharma AB
- Target Recruit Count
- 128
- Registration Number
- NCT07138378
- Locations
- 🇮🇳
QPS Bioserve India Pvt Limited, Hyderabad, India
An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL®
Phase 1
Completed
- Conditions
- Drug-drug Interaction Study
- Interventions
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Xspray Pharma AB
- Target Recruit Count
- 18
- Registration Number
- NCT06145217
- Locations
- 🇮🇳
QPS Bioserve India Pvt Limited, Hyderabad, India
Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects
Phase 1
Completed
- Conditions
- PharmacokineticsBioavailability
- Interventions
- Drug: XS005 Sorafenib Tablet A - Period 2Drug: XS005 Sorafenib Capsule A - Period 1Drug: XS005 Sorafenib Capsule A - Period 2Drug: XS005 Sorafenib Capsule A - Period 3Drug: XS005 Sorafenib Tablet A - Period 1Drug: XS005 Sorafenib Tablet A - Period 3
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Xspray Pharma AB
- Target Recruit Count
- 15
- Registration Number
- NCT05967377
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions
Phase 1
Completed
- Conditions
- Biological Availability
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Xspray Pharma AB
- Target Recruit Count
- 110
- Registration Number
- NCT05439408
- Locations
- 🇮🇳
QPS Bioserve India Pvt Limited, Hyderabad, India
- Prev
- 1
- 2
- Next
News
No news found